These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

983 related articles for article (PubMed ID: 29198946)

  • 61. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
    Sinn DH; Cho JY; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    PLoS One; 2015; 10(4):e0124434. PubMed ID: 25923439
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS; Park MH; Jeon GS
    Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
    Zhu K; Chen J; Lai L; Meng X; Zhou B; Huang W; Cai M; Shan H
    Radiology; 2014 Jul; 272(1):284-93. PubMed ID: 24708192
    [TBL] [Abstract][Full Text] [Related]  

  • 66. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging.
    Su TH; Liao SH; Hong CM; Liu CJ; Tseng TC; Liu CH; Yang HC; Chen PJ; Chen DS; Chen CL; Adhoute X; Bourlière M; Kao JH
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2179-2186. PubMed ID: 31062879
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
    Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
    World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis.
    Qi X; Wang D; Su C; Li H; Guo X
    Oncotarget; 2015 Jul; 6(21):18715-33. PubMed ID: 26243835
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
    Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
    J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma.
    Yu Y; Lang QB; Chen Z; Li B; Yu CQ; Zhu DZ; Huang XQ; Zhai XF; Ling CQ
    Chin Med J (Engl); 2009 Sep; 122(17):1990-5. PubMed ID: 19781383
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sorafenib plus transcatheter arterial chemoembolization with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma.
    Sun B; Chen L; Lei Y; Zhang L; Sun T; Liu Y; Zheng C
    Br J Radiol; 2024 Jun; 97(1159):1320-1327. PubMed ID: 38711192
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.
    Zhong JH; Xiang BD; Gong WF; Ke Y; Mo QG; Ma L; Liu X; Li LQ
    PLoS One; 2013; 8(7):e68193. PubMed ID: 23874536
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.
    Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
    HPB (Oxford); 2010 Apr; 12(3):174-80. PubMed ID: 20590884
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma.
    Kong JY; Li SM; Fan HY; Zhang L; Zhao HJ; Li SM
    Medicine (Baltimore); 2018 Aug; 97(33):e11872. PubMed ID: 30113483
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy.
    Ye Z; Deng Z; Jiang S; Wang T; Liu L; Jiang K; Zhang Y
    Cardiovasc Intervent Radiol; 2021 Sep; 44(9):1394-1402. PubMed ID: 33948697
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Experience with Sorafenib in 3 Hospitals in Sao Paulo.
    Camargo-Pinheiro-Alves R; Viera-Alves DE; Malzyner A; Gampel O; Almeida-Costa TF; Guz B; Poletti P
    Ann Hepatol; 2019; 18(1):172-176. PubMed ID: 31113587
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?
    Jianyong L; Lunan Y; Wentao W; Yong Z; Bo L; Tianfu W; Minqing X; Jiaying Y
    Medicine (Baltimore); 2014 Nov; 93(26):e180. PubMed ID: 25474433
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study.
    Yuan J; Yin X; Tang B; Ma H; Zhang L; Li L; Chen R; Xie X; Ren Z
    Biomed Res Int; 2019; 2019():2141859. PubMed ID: 31467872
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study.
    Patidar Y; Chandel K; Condati NK; Srinivasan SV; Mukund A; Sarin SK
    J Clin Exp Hepatol; 2022; 12(3):745-754. PubMed ID: 35677519
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
    Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Yokosuka O; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y;
    Gut; 2020 Aug; 69(8):1492-1501. PubMed ID: 31801872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.